update on keynote 522, the current standard of care for triple negative breast cancer.
Published 5 months ago • 225 plays • Length 0:50Download video MP4
Download video MP3
Similar videos
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
0:37
management for residual disease in tnbc after chemo-immunotherapy
-
16:09
triple negative breast cancer algorithm - oncbrothers (rohit & rahul gosain) w/ dr. shipra gandhi
-
18:38
how to treat triple negative breast cancer | dr. ruth o'regan chair & dr. anna weiss
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
13:51
esmo 2023 breast cancer highlights – keynote 756, tropion-breast01, keynote 52 | onc brothers
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
16:56
tnbc sabcs 2022 highlights - oncbrothers (rohit and rahul gosain) with dr. maryam lustberg
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
0:58
highlights from esmo 2023 in breast cancer – keynote 756, tropion-breast01, keynote 52
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
6:16
latest on immunotherapy in triple-negative breast cancer - medpage today
-
11:53
new developments in triple-negative breast cancer therapies - medpage today
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
5:49
neoadjuvant treatment for triple-negative breast cancer
-
4:54
proposed clinical trial could change triple negative breast cancer treatment
-
1:08
review of recent progress in immunotherapy in triple negative breast cancer schmid 1